Press Release

June 13, 2021
1 min read

Cedars-Sinai Cancer names thoracic medical oncology director


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Sukhmani K. Padda, MD, has been selected to direct thoracic medical oncology at Cedars-Sinai Cancer.

Padda’s research focuses on therapies for thoracic cancers. She has a particular interest in improving treatment for patients with rare thoracic tumors — such as thymic malignancies and lung neuroendocrine tumors — and genomic subsets of lung cancer, such as KRAS- and EGFR-positive tumors. Padda also conducts research into tumor biomarkers to help ensure optimal treatment.

“There are a lot of success stories in lung cancer, but the area still needs improvement,” Padda said in a press release. “A great deal of work is being done with targeted treatments and how novel treatment approaches can overcome resistance to targeted therapies. There are a lot of interesting questions; I’m excited to help look for the answers.”

Sukhmani K. Padda, MD
Sukhmani K. Padda

Padda’s priorities in her new role will include expanding development of clinical trials.

Padda previously served as assistant professor of medicine and phase 1 clinical research group leader at Stanford University.

“Dr. Padda is a key addition to our faculty," Dan Theodorescu, MD, PhD, director of Cedars-Sinai Cancer, said in the release. "Her clinical expertise and research will greatly contribute to positioning our lung cancer program as one of the best in the nation, while providing Cedars-Sinai Cancer patients with exciting new options for lung cancer treatment.”